article thumbnail

Decoding Epigenetic Triggers: Unveiling the Mechanisms Driving Hepatocellular Carcinoma

Scienmag

In hepatic malignancies, dysregulation of histone acetylation is especially prominent, with overexpressed histone deacetylases (HDACs) fostering chromatin condensation and gene silencing. This epigenetic silencing mechanism extends to tumor suppressors, further exacerbating oncogenic shift.

DNA 59
article thumbnail

EHMT2’s Role in Prader-Willi Genomic Imprinting

Scienmag

This RNA-dependent targeting mechanism expands the functional repertoire of non-coding RNAs from passive bystanders to active participants in epigenetic gene silencing. The authors describe how specific long non-coding RNAs guide EHMT2 to target loci, orchestrating locus-specific chromatin modifications.

Genome 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Alnylam Promotes Pushkal Garg to Chief R&D Officer

The Pharma Data

His scientific and operational leadership has been central to Alnylam’s emergence as a pioneer of RNAi therapeutics, a novel modality that harnesses the body’s natural gene-silencing mechanisms to selectively inhibit disease-causing genes.

article thumbnail

Male-Linked miRNA Drives Bird Sex Dosage

Scienmag

It challenges the prevailing notion that dosage compensation mechanisms predominantly rely on chromosome-wide gene silencing or upregulation, instead highlighting a nuanced interplay of transcriptional, translational, and post-transcriptional processes that are sex-specific and gene-specific.

article thumbnail

NICE recommends gene silencing therapy for porphyria patients on NHS

Pharma Times

Givlaari uses ‘gene silencing’ RNA interference technology, to target the production of pathogenic compounds in people AHP

article thumbnail

Novartis buys a preclinical biotech and its RNA drug technology

Bio Pharma Dive

For $500 million, Novartis will acquire DTx Pharma and its preclinical neurological disease drugs, marking the Swiss company’s latest investment in gene-silencing medicines.

article thumbnail

Gene Silencing Porphyria Treatment, Givlaari, Finally Wins Over England’s NICE Amid Stellar Long-Term Data

XTalks

After initial rejection from the National Institute for Health and Care Excellence (NICE) last year, the non-departmental public body of the Department of Health in England has now given the green light to the gene silencing treatment Givlaari (givosiran) for the treatment of the rare metabolic disorder, acute intermittent porphyria (AIP).